Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England's prescription data during the COVID-19 pandemic (January 2019 to October 2020).
Therapeutic advances in cardiovascular disease（2022）
摘要
A concerning decline in uptake of CVD therapies for chronic heart disease was observed. Accessible screening and treatment alongside financial relief on prescription levies are needed. A video abstract is (4 min 51 s) available: https://bit.ly/39gvEHi.
更多查看译文
关键词
COVID-19,SARS-CoV-2,analysis of variance,angiotensin II,angiotensin-converting enzyme inhibitors,bendroflumethiazide,calcium channel blockers,cardiovascular diseases,colesevelam hydrochloride,communicable disease control,confidence intervals,delivery of health care,diuretics,doxazosin,ezetimibe,fibrinolytic agents,health services accessibility,health status disparities,heart diseases,hydroxymethylglutaryl-CoA reductase inhibitors,indapamide,interrupted time-series analysis,ivabradine,life expectancy,medication adherence,medicine,midodrine,nicorandil,nitrates,pandemics,pharmacies,potassium sparing,prescriptions,primary health care,ranolazine,retrospective studies,sodium potassium chloride symporter inhibitors
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要